200 related articles for article (PubMed ID: 38540761)
21. Cytoplasmic SIRT1 promotes paclitaxel resistance in ovarian carcinoma through increased formation and survival of polyploid giant cancer cells.
Xu H; Zeng S; Wang Y; Yang T; Wang M; Li X; He Y; Peng X; Li X; Qiao Q; Zhang J
J Pathol; 2023 Oct; 261(2):210-226. PubMed ID: 37565313
[TBL] [Abstract][Full Text] [Related]
22. Development and characterization of nanobodies that specifically target the oncogenic Phosphatase of Regenerating Liver-3 (PRL-3) and impact its interaction with a known binding partner, CNNM3.
Smith CN; Kihn K; Williamson ZA; Chow KM; Hersh LB; Korotkov KV; Deredge D; Blackburn JS
PLoS One; 2023; 18(5):e0285964. PubMed ID: 37220097
[TBL] [Abstract][Full Text] [Related]
23. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.
Xue C; Yao Q; Gu X; Shi Q; Yuan X; Chu Q; Bao Z; Lu J; Li L
Signal Transduct Target Ther; 2023 May; 8(1):204. PubMed ID: 37208335
[TBL] [Abstract][Full Text] [Related]
24. Phosphatase regenerating liver 3 participates in Integrinβ1/FAK-Src/MAPK signaling pathway and contributes to the regulation of malignant behaviors in hepatocellular carcinoma cells.
Chen G; Zhang Z; Li J; Hu C; Gao D; Chen J; Zhang L; Xie X
J Gastrointest Oncol; 2023 Apr; 14(2):863-873. PubMed ID: 37201051
[TBL] [Abstract][Full Text] [Related]
25. PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types.
Chia PL; Ang KH; Thura M; Zeng Q
Theranostics; 2023; 13(6):1876-1891. PubMed ID: 37064866
[TBL] [Abstract][Full Text] [Related]
26. A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.
Chee CE; Ooi M; Lee SC; Sundar R; Heong V; Yong WP; Ng CH; Wong A; Lim JSJ; Tan DSP; Soo R; Tan JTC; Yang S; Thura M; Al-Aidaroos AQ; Chng WJ; Zeng Q; Goh BC
Target Oncol; 2023 May; 18(3):391-402. PubMed ID: 37060431
[TBL] [Abstract][Full Text] [Related]
27. PRL-1/2 phosphatases control TRPM7 magnesium-dependent function to regulate cellular bioenergetics.
Hardy S; Zolotarov Y; Coleman J; Roitman S; Khursheed H; Aubry I; Uetani N; Tremblay ML
Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2221083120. PubMed ID: 36972446
[TBL] [Abstract][Full Text] [Related]
28. PTPN14 promotes gastric cancer progression by PI3KA/AKT/mTOR pathway.
Li H; Guan B; Liu S; Liu H; Song L; Zhang G; Zhao R; Zhou C; Gao P
Cell Death Dis; 2023 Mar; 14(3):188. PubMed ID: 36898991
[TBL] [Abstract][Full Text] [Related]
29. Disruption of Ovarian Cancer STAT3 and p38 Signaling with a Small-Molecule Inhibitor of PTP4A3 Phosphatase.
Lazo JS; Isbell KN; Vasa SA; Llaneza DC; Rastelli EJ; Wipf P; Sharlow ER
J Pharmacol Exp Ther; 2023 Mar; 384(3):429-438. PubMed ID: 36627205
[TBL] [Abstract][Full Text] [Related]
30. The Deubiquitinating Enzyme USP4 Functions as an Oncoprotein in Gastric Cancer and Mediates NF-κB Signaling by Regulating PRL-3 Expression.
Tao Y; You W
Front Biosci (Landmark Ed); 2022 Oct; 27(10):286. PubMed ID: 36336860
[TBL] [Abstract][Full Text] [Related]
31. Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications.
Yang Q; Xu J; Gu J; Shi H; Zhang J; Zhang J; Chen ZS; Fang X; Zhu T; Zhang X
Adv Sci (Weinh); 2022 Dec; 9(34):e2201609. PubMed ID: 36253096
[TBL] [Abstract][Full Text] [Related]
32. Characterizing
Jin X; Shi H; Li Z; Li H; Ma H; Shi X
J Oncol; 2022; 2022():2717056. PubMed ID: 36213837
[TBL] [Abstract][Full Text] [Related]
33. Organization, dynamics and mechanoregulation of integrin-mediated cell-ECM adhesions.
Kanchanawong P; Calderwood DA
Nat Rev Mol Cell Biol; 2023 Feb; 24(2):142-161. PubMed ID: 36168065
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analyses unveil novel genomic and immunological characteristics of micropapillary pattern in lung adenocarcinoma.
Huo Y; Sun L; Yuan J; Zhang H; Zhang Z; Zhang L; Huang W; Sun X; Tang Z; Feng Y; Mo H; Yang Z; Zhang C; Yu Z; Yue D; Zhang B; Wang C
Front Oncol; 2022; 12():931209. PubMed ID: 35992814
[TBL] [Abstract][Full Text] [Related]
35. Dissecting the role of protein phosphorylation: a chemical biology toolbox.
Bilbrough T; Piemontese E; Seitz O
Chem Soc Rev; 2022 Jul; 51(13):5691-5730. PubMed ID: 35726784
[TBL] [Abstract][Full Text] [Related]
36. PRL-3 and MMP9 Expression and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells From Patients With Colorectal Cancer: Potential Value in Clinical Practice.
Hong XC; Liang QL; Chen M; Yang HX; Huang J; Yi SL; Wang ZW; Liang HY; Zhang DY; Huang ZY
Front Oncol; 2022; 12():878639. PubMed ID: 35574414
[TBL] [Abstract][Full Text] [Related]
37. NF-κB as a regulator of cancer metastasis and therapy response: A focus on epithelial-mesenchymal transition.
Mirzaei S; Saghari S; Bassiri F; Raesi R; Zarrabi A; Hushmandi K; Sethi G; Tergaonkar V
J Cell Physiol; 2022 Jul; 237(7):2770-2795. PubMed ID: 35561232
[TBL] [Abstract][Full Text] [Related]
38. Celecoxib attenuates hepatocellular proliferative capacity during hepatocarcinogenesis by modulating a PTEN/NF-κB/PRL-3 pathway.
Zhang C; Zhou J; Hu J; Lei S; Yuan M; Chen L; Wang G; Qiu Z
RSC Adv; 2019 Jul; 9(36):20624-20632. PubMed ID: 35515542
[TBL] [Abstract][Full Text] [Related]
39. Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment.
Li W; Li F; Zhang X; Lin HK; Xu C
Signal Transduct Target Ther; 2021 Dec; 6(1):422. PubMed ID: 34924561
[TBL] [Abstract][Full Text] [Related]
40. Intertumoral Heterogeneity of Primary Breast Tumors and Synchronous Axillary Lymph Node Metastases Reflected in IHC-Assessed Expression of Routine and Nonstandard Biomarkers.
Kuncman W; Orzechowska M; Kuncman Ł; Kordek R; Taran K
Front Oncol; 2021; 11():660318. PubMed ID: 34804912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
